Lisa H Lancaster
Overview
Explore the profile of Lisa H Lancaster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2068
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mattos W, Khalil N, Spencer L, Bonella F, Folz R, Rolf J, et al.
Am J Respir Crit Care Med
. 2024 Mar;
210(4):435-443.
PMID: 38484130
Idiopathic pulmonary fibrosis is a fatal and progressive disease with limited treatment options. We sought to assess the efficacy and safety of CC-90001, an oral inhibitor of c-Jun N-terminal kinase...
2.
Donoghue L, Stockwell A, Neighbors M, Sheng R, Prabhakaran R, Wolters P, et al.
Am J Respir Crit Care Med
. 2023 Jan;
207(7):941-944.
PMID: 36603154
No abstract available.
3.
Salisbury M, Markin C, Wu P, Cogan J, Mitchell D, Liu Q, et al.
Am J Respir Crit Care Med
. 2022 Aug;
207(2):208-211.
PMID: 36036734
No abstract available.
4.
Copeland C, Donnelly E, Mehrad M, Ding G, Markin C, Douglas K, et al.
Ann Am Thorac Soc
. 2022 Jul;
19(12):2003-2012.
PMID: 35877079
Heterogeneous characteristics are observed in familial pulmonary fibrosis (FPF), suggesting that nongenetic factors contribute to disease manifestations. To determine the relationship between environmental exposures and disease characteristics of FPF, including...
5.
Raghu G, Mouded M, Chambers D, Martinez F, Richeldi L, Lancaster L, et al.
Am J Respir Crit Care Med
. 2022 Jun;
206(9):1128-1139.
PMID: 35771569
Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. To evaluate the efficacy and safety of BG00011, an anti-αβ IgG1 monoclonal antibody, in the treatment of patients with IPF. In...
6.
Swain S, Nishino M, Lancaster L, Li B, Nicholson A, Bartholmai B, et al.
Cancer Treat Rev
. 2022 Apr;
106:102378.
PMID: 35430509
Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an adverse event associated with T-DXd; in most cases, it...
7.
Rahaghi F, Kolaitis N, Adegunsoye A, de Andrade J, Flaherty K, Lancaster L, et al.
Chest
. 2022 Feb;
162(1):145-155.
PMID: 35176276
Background: Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) and is associated with worse outcomes and increased mortality. Evaluation of PH is recommended in lung transplant...
8.
Copeland C, Lancaster L
Front Med (Lausanne)
. 2021 Nov;
8:743977.
PMID: 34722582
Progressive fibrosing interstitial lung diseases (PF-ILD) consist of a diverse group of interstitial lung diseases (ILD) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and...
9.
Maher T, Brown K, Kreuter M, Devaraj A, Walsh S, Lancaster L, et al.
Eur Respir J
. 2021 Jul;
59(2).
PMID: 34210788
Background: The INBUILD trial investigated nintedanib placebo in patients with progressive fibrosing interstitial lung diseases (ILDs). We investigated the decline in forced vital capacity (FVC) in subgroups based on the...
10.
Blackwell T, Hewlett J, Mason W, Martin S, Del Greco J, Ding G, et al.
Ann Am Thorac Soc
. 2021 Mar;
18(8):1291-1297.
PMID: 33740394
Human herpesviruses Epstein-Barr virus and cytomegalovirus are frequently detectable in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and could contribute to disease pathogenesis. With the goal of inhibiting...